I show below a YouTube link to Andrew Newland, the CEO of Angle (LON:AGL), who here considers last Friday’s announcement of Angle’s success in developing Parsortix, a liquid biopsy system which detects cancer. As most of you know, it is customary to cut the patient open, which is relatively an extremely expensive operation. Parsortix just takes blood and pronounces – although it must be stressed that this approach has yet to be approved by regulatory authorities.
However, last Friday’s contract announcement means that AGL has been accepted by a pharma major. This could not have occurred in the absence of the pharma major being reasonably confident that all this would work.
AGL is capitalised at 98p at £210m. This is a trifling figure should all go as planned. It is no exaggeration to expect AGL, if successful, to be worth billions of pounds.
(Biographical note: Andrew’s brother, Dr Richard Newland, a former GP, trained a winner of the Grand National – Pineau de Re – in 2014. Andrew is a chartered accountant by upbringing. I met him perhaps five years ago at a presentation arranged by Jeremy Lyon and the late Bob Catto. I liked the cut of his jib. Family Cawkwell own c. 500,000 AGL.)
Here is the link:
Technically, AGL moved into new high ground on Friday. I think it most unlikely that it stops here. You can typically buy 25,000 shares at the touch – although things may prove different on the day.